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Abstract
Invasive fungal infections (IFIs) are a major cause of morbidity and mortality in haematopoietic stem cell transplant (HCT) recipients and
patients with haematological malignancies. Early treatment initiation is vital for improving survival, but is hampered by difﬁculties in
timely diagnosis. Prophylaxis with a broad-spectrum antifungal, such as voriconazole, has the potential to decrease the incidence of
IFI in haematology patients. Based on a growing body of data, voriconazole appears to be effective for the primary and secondary
prevention of IFIs in HCT recipients, with generally good tolerability.
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Introduction
Invasive fungal infections (IFIs) are a signiﬁcant cause of mor-
bidity and mortality in haematology patients. Haematopoietic
stem cell transplant (HCT) recipients and patients with hae-
matological malignancies are particularly vulnerable, as a con-
sequence of their underlying condition, its treatment, or
prolonged immunosuppression [1–6]. Invasive aspergillosis
(IA) is the most important IFI in these populations and is the
leading cause of infection-related death in HCT recipients
[7]. The onset of invasive Aspergillus infection following HCT
appears to be bimodal, occurring more frequently during the
graft-versus-host disease (GvHD) period late after engraft-
ment [3,8,9]. Patients undergoing autologous HCT rarely
present with IA and have a distinctly lower attributable mor-
tality rate than allograft recipients [10]. Besides IA, other
invasive mould infections and invasive candidiasis are also
fairly common [3,6,8,11,12]. Recent data show that about
three-quarters of IFIs in HCT patients are caused by moulds,
mostly in the form of IA (59–71%), with the remainder
caused by Candida spp. [10,13,14]. Furthermore, invasive
mould infections, especially those caused by Aspergillus,
appear to be becoming increasingly frequent in various hae-
matology populations [3,4,8].
These trends are probably linked to the growing number
of at-risk patients (e.g. elderly patients undergoing reduced-
intensity conditioning HCT, solid organ transplant recipients,
and critically ill patients) as well as the increasing prevalence
of risk factors rendering patients susceptible to IFIs in gen-
eral and invasive mould infections in particular. Such risk fac-
tors include cytotoxic chemotherapy, neutropenia, GvHD,
immunosuppressant therapy, broad-spectrum antibiotics, use
of intravenous catheters, parenteral nutrition and renal fail-
ure [1,3]. In haematology patients, the risk for developing an
IFI depends strongly on the severity and duration of myelo-
suppression and immunosuppression [15]. The overall devel-
opments in epidemiology are of concern because IFIs are
associated with substantial mortality. In Europe, mortality
rates range from 27 to 94% for IA and from 28 to 59% for
invasive candidiasis [10,16–24].
Although early initiation of therapy is vital for improving
treatment outcomes, the timely diagnosis and treatment of
IFIs pose considerable challenges [3,25,26]. Given the lack of
validated early treatment strategies, mould-active prophylaxis
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may currently be the most attractive option for the manage-
ment of IFIs in speciﬁc groups of haematology patients, until
tests for the early detection of IFI have become more reli-
able [26–30]. This preventative approach has the potential of
decreasing IFI incidence and concurrently improving survival
in haematology patients; however, data from recent clinical
trials suggest that it does not entirely avoid the need for
additional empirical or pre-emptive therapy [31–34].
There are also some concerns about the widespread
application of antifungal prophylaxis, such as induction of
antimicrobial resistance, shifts in epidemiology, avoidable
drug toxicity and costs, and considerable variability in the
plasma levels of certain antifungals [15,27,35]. This review
will address current issues in antifungal prophylaxis for HCT
recipients and haematological malignancy patients, with a par-
ticular focus on recent data supporting the potential value of
voriconazole in this setting.
Antifungal prophylaxis
The use of any chemoprophylaxis in medicine ought to be
supported by a number of key tenets. For instance, the dis-
ease to be prevented should be associated with a high mor-
tality rate, and the preventative agent should have an
acceptable efﬁcacy and safety proﬁle. Furthermore, optimum
IFI prophylaxis requires the selection of patients at highest
risk of invasive fungal disease, to limit drug exposure to those
individuals who are most likely to beneﬁt from this strategy
[36,37]. Novel approaches toward the identiﬁcation of high-
risk patients have shown the importance of host innate
immunity, with several genetic polymorphisms (i.e. of TLR4,
IL10, DECTIN-1, and the plasminogen gene) having potential as
speciﬁc risk markers [35,38]. Some authors propose to
restrict prophylaxis with broad-spectrum azoles to those
institutions that have a relatively high incidence of invasive
mould infections or that do not routinely employ effective
strategies for early diagnosis and treatment [36,39]. However,
so far there is no consensus on how to deﬁne populations of
haematology patients that are at ‘high-risk for IFI’ on the basis
of a minimum IFI incidence rate or a minimum number
needed-to-treat, and in whom primary antifungal prophylaxis
may therefore be preferable to other management
approaches. Besides chemoprophylaxis, protective isolation in
conjunction with the use of high-efﬁciency particulate air ﬁl-
tration systems may also be useful for the prevention of sys-
temic mould infections in patients undergoing allogeneic HCT
or chemotherapy for acute leukaemia [1,36].
The optimal duration of antifungal prophylaxis in haema-
tology patients also remains to be conﬁrmed. In HCT recipi-
ents, prophylactic therapy may need to be administered for a
minimum of 6 months following transplant [15], in particular
when considering the increasing frequency of late-onset IA
[8,26]. The efﬁcacy of antifungal prophylaxis during this time
may partially depend on the degree of immunosuppression,
as indicated by biological markers (e.g. levels of CD4 T lym-
phocytes) [15]. Also still unknown are the most effective
agents for antifungal prophylaxis in HCT recipients or
patients receiving chemotherapy for haematological disease
(Table 1) [31,32,34,40–48], even though mould-active azoles
seem to have the most potential in these settings. Among
that class of agents, the second-generation, broad-spectrum
triazole voriconazole is emerging as a new option for pri-
mary and secondary antifungal prophylaxis.
The potential of voriconazole as antifungal
prophylaxis
Voriconazole is currently indicated for the treatment of inva-
sive aspergillosis, candidaemia in non-neutropenic patients,
and serious infections caused by Scedosporium and Fusarium
spp. Furthermore, in Europe the agent is licensed for the treat-
ment of ﬂuconazole-resistant serious invasive Candida infec-
tions and in the USA for oesophageal candidiasis and
disseminated Candida infections in skin, abdomen, kidney, blad-
der wall and wounds [49,50]. This variety of indications is
reﬂected by the broad in vitro spectrum of voriconazole against
yeasts and moulds, including Aspergillus spp., Candida spp., Fusa-
rium spp., Scedosporium apiospermum, dematiaceous moulds,
Cryptococcus neoformans and dimorphic fungi. Of note, vorico-
nazole is not active against the zygomycetes and may have
reduced activity against certain strains of Candida glabrata and
Candida albicans that have acquired ﬂuconazole resistance [51].
The extended spectrum of voriconazole gives it potential
value as a prophylactic agent. The in vitro coverage and docu-
mented clinical efﬁcacy of voriconazole against the majority
of fungal pathogens [20,51–55] may make it particularly useful
for the prevention of IFIs in the haematology setting, where
invasive mould infections play a prominent role. Of note,
voriconazole is now generally recommended as ﬁrst-line
treatment for proven or probable IA [56–60], the most signif-
icant systemic fungal disease affecting haematology popula-
tions; a recent mixed-treatment comparison suggested that
voriconazole may be the most effective antifungal for improv-
ing patient survival in the setting of directed therapy [61]. On
the other hand, the very fact that voriconazole is widely con-
sidered the standard treatment for documented IA may pose
an issue when using mould-active azoles prophylactically in
the same patient population, because of the risk of selection
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of resistant strains in patients who fail prophylaxis. Few alter-
native options with similar efﬁcacy and tolerability to vorico-
nazole exist for the treatment of potential breakthrough IA;
generally, in case of breakthrough IA under azole prophylaxis
it is recommended to switch to another class of mould-active
antifungals, preferably liposomal amphotericin B [59]. The
availability of both oral and intravenous formulations for
voriconazole is also a possible advantage in IFI treatment and
prophylaxis: whereas oral agents have the potential to be
more convenient and cost-effective, the concurrent availabil-
ity of an intravenous formulation allows for continued unin-
terrupted treatment in patients with intestinal GvHD,
diarrhoea or mucositis—fairly common conditions in haema-
tology patients—who may be unsuitable for oral administra-
tion; only oral posaconazole is currently available, and
intravenous itraconazole is only available in some countries.
In terms of drug bioavailability, antifungal penetration into rel-
evant target tissues is also important. Following administra-
tion of oral voriconazole as antifungal prophylaxis, the agent
seems to exhibit good tissue penetration into the lungs, the
most common primary infection site in IA [62]. Finally, while
voriconazole is associated with some important and well-
characterized adverse events, its use is generally well toler-
ated, even for extended periods of time [32,51,63]. Long-
term tolerability of antifungal prophylaxis is vital in haematol-
ogy patients, to allow for the substantial treatment durations
often required in this population.
As mentioned above, voriconazole has several potential
beneﬁts as a prophylactic agent; however, its use is also asso-
ciated with a number of concerns and issues. First and fore-
most, there is the possibility of serious adverse events, such
as prolonged visual disturbances, QT-interval prolongation
and hepatic toxicity. These events seem to occur mainly in
severely ill patients and in those with relevant underlying con-
ditions, and close monitoring of visual and liver function is
therefore strongly recommended [49–51]. In addition, there
have been a small number of reports of squamous cell carci-
noma as well as of melanoma during long-term voriconazole
treatment [64,65], potentially associated with the photosensi-
tivity effect of this agent. However, the contribution of voric-
onazole to the development of squamous cell carcinoma has
not been established. Voriconazole and other members of
the azole class, such as posaconazole, also give rise to con-
cerns regarding their considerable potential for drug–drug
interactions with commonly administered concomitant medi-
cations [49–51]. For example, interactions between hepatical-
ly metabolized chemotherapy agents (e.g. vinca alkaloids and
anthracyclines) and mould-active azoles may result in unac-
ceptable toxicity, unless appropriate dose adjustments can be
established [26,66]. Studies have also shown that in combina-T
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tion with the chemotherapeutic drug/conditioning agent
cyclophosphamide, itraconazole may cause clinically signiﬁcant
interactions, including hypertension, neurotoxicity and gastro-
intestinal toxicity [40]; however, similar interactions have so
far not been reported for other mould-active azoles.
Voriconazole prophylaxis may also be complicated by the
potential need for voriconazole therapeutic drug monitoring,
given the considerable intra-subject variability in the drug’s
pharmacokinetics. Regular monitoring of voriconazole plasma
levels and subsequent dose adjustments have been proposed
to improve the efﬁcacy and safety of voriconazole prophylaxis
[67–69]. However, so far a plasma concentration range corre-
lating with clinical efﬁcacy could not be formally established in
any of the large prospective randomized studies with vorico-
nazole [51]; the non-linear pharmacokinetics of voriconazole
probably contribute to the difﬁculties in determining such a
relationship. Voriconazole drug monitoring may have a beneﬁt
in terms of safety and compliance issues, because higher
plasma levels have been shown to correlate with neurological
toxicity [70] and lower levels—which have been shown to
correlate with poor efﬁcacy [70]—may be associated with
poor compliance or poor intestinal absorption. Another
report, however, suggested that voriconazole therapeutic
drug monitoring was unlikely to be more useful than routine
monitoring of liver function tests in reducing drug-related hep-
atotoxicity [71]. Other currently available extended-spectrum
azoles (i.e. itraconazole and posaconazole) also have issues
regarding therapeutic drug monitoring and pharmacokinetic
variability, which is particularly problematic in allogeneic HCT
recipients with intestinal GvHD who are receiving an oral
azole formulation [8,72,73]. In this regard, the clinical judg-
ment of the physician is important. Finally, it has been sug-
gested that the rise in zygomycosis observed at some
transplant centres could be associated with the local use of
voriconazole prophylaxis. However, this potential correlation
remains disputed: such epidemiological shifts may actually be
the result of evolving transplant practices (including more diag-
nostic investigations, more effective anti-Aspergillus prophylaxis
and changes in immunosuppression) that result in improved
patient survival, rather than being the result of selective pres-
sure [51,74].
Evidence from clinical trials
Primary antifungal prophylaxis
Fluconazole has been evaluated in well-designed randomized
controlled antifungal prophylaxis studies. In two placebo-con-
trolled, double-blind trials mainly conducted in allogeneic
HCT recipients, 400 mg/day ﬂuconazole was signiﬁcantly
more effective than placebo in reducing IFIs and attributable
mortality [44,51,75]. Other agents successfully evaluated
against placebo for primary antifungal prophylaxis in haema-
tology patients include intravenous [76] and inhaled liposo-
mal amphotericin B, although the latter was only effective for
the prevention of pulmonary IA and all patients in the
respective study received concomitant ﬂuconazole [42].
Comparative trials of ﬂuconazole against itraconazole for pri-
mary antifungal prophylaxis in allogeneic HCT recipients
failed to show a survival advantage for itraconazole, despite
the latter agent’s broader spectrum [47,77,78]. However,
some of these studies showed a signiﬁcant reduction in
breakthrough IFIs [47,78] with itraconazole compared with
ﬂuconazole. The echinocandin micafungin was found to be
superior to ﬂuconazole in reducing suspected, probable, or
proven IFIs with equivalent mortality in a combined popula-
tion of autologous and allogeneic HCT recipients [33]. How-
ever, this superiority was achieved mainly through the higher
incidence of suspected infections in the ﬂuconazole arm; the
incidence of proven and probable IFIs was extremely low in
this study (i.e. about 2% in each treatment arm) and did not
differ signiﬁcantly between micafungin and ﬂuconazole [33].
Finally, in allogeneic HCT recipients with GvHD, who consti-
tute a particularly high-risk population, posaconazole was
found to be superior to ﬂuconazole in reducing IA incidence
and IFI-related mortality. However, this beneﬁt was signiﬁ-
cant only in patients with acute GvHD, and not in those with
chronic GvHD. It should also be noted that in this study 18
patients (6.0%) treated with posaconazole reported serious
treatment-related adverse events associated with abnormal
liver function (i.e. bilirubinemia, increased hepatic enzymes,
increased c-glutamyltransferase, hepatocellular damage and
abnormal hepatic function), compared with ten patients
(3.3%) in the ﬂuconazole arm [46]. Another study showed
posaconazole to be superior to ﬂuconazole or itraconazole
in reducing IFI incidence as well as improving survival when
used as primary prophylaxis in acute myeloid leukaemia and
myelodysplastic syndrome patients with chemotherapy-
induced neutropenia [31].
Recently, two large clinical studies have also evaluated
voriconazole as primary antifungal prophylaxis following allo-
geneic HCT. The ﬁrst was a randomized, double-blind trial
comparing voriconazole (200 mg twice daily) with ﬂuconaz-
ole (400 mg daily) in allograft recipients ‡2 years of age who
were receiving full-intensity conditioning regimens and were
considered to be at standard risk of IFI [34]; patients at the
highest risk of IFI were intentionally excluded to minimize
the effect of competing non-fungal-related causes of death, a
major potential confounder in any study of antifungal prophy-
laxis [79]. Study prophylaxis was administered for a minimum
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duration of 100 days, which could be extended to 180 days
for those patients who at day 100 were receiving prednisone
(‡1 mg/kg daily) and/or had CD4 T-lymphocyte counts of
<200/lL (in case they were recipients of T-cell-depleted
grafts). Serum galactomannan levels were evaluated twice
weekly for 60 days in all patients and then once or twice
weekly until day 100, depending on the presence and sever-
ity of GvHD. An intensive diagnostic process was conducted
for all patients who exhibited a positive galactomannan assay
result, suspicious radiology or signs or symptoms indicative
of an IFI. If a patient presented with a possible IFI, empiric
antifungal therapy (with liposomal amphotericin B or caspo-
fungin) was permitted for a maximum of 14 days until the
outcome of detailed diagnostics became available. The pri-
mary endpoint of the study was fungal-free survival at
6 months post-transplant in the intent-to-treat population
[34].
After randomization, 295 patients were assigned to ﬂuco-
nazole and 305 to voriconazole. Among the total of 600
patients, most had leukaemia as their underlying condition, in
the form of acute myeloid leukaemia (34–44%), acute lym-
phoid leukaemia (19–22%), or chronic myeloid leukaemia
(14–20%); myelodysplastic syndrome (16–17%) and non-
Hodgkin’s lymphoma (7%) were less common. The median
age of the study participants was 43 years (range: 2–65); 92%
of patients were older than 18 years, 55% were male, 96%
had a matched donor, and 55–57% had received their trans-
plant from a matched related donor. Overall, there were no
signiﬁcant differences between the two arms in terms of
baseline demographics, including disease type, IFI risk, or
transplant characteristics. Rates of engraftment, acute or
chronic GvHD, and of non-fungal infections were also not
signiﬁcantly different between the two treatment groups. All
randomized patients were to be followed up for a total of
12 months [34].
Fungal-free survival at 6 months was 78% with voriconaz-
ole and 75% with ﬂuconazole, and at 12 months was 64%
with voriconazole and 65% with ﬂuconazole. The differences
between treatment groups were not signiﬁcant. There were
also no differences in overall survival between the two
agents at 6 and 12 months (Fig. 1) [34]. Furthermore, rates
of severe AEs and early withdrawal from the study were
similar for the two treatment groups. During the course of
the trial a total of 28 proven, 33 probable, 18 presumptive
(deﬁned as presence of at least one clinical criterion for
lower respiratory tract infection, with results from broncho-
scopic examination excluding other potential causes), and 75
possible IFIs were recorded. The cumulative incidence rates
of proven, probable and presumptive IFI were similar
between the two arms: 7.3% for voriconazole and 11.2% for
ﬂuconazole at 6 months (p 0.12) and 12.7% and 13.7% at
12 months (p 0.59), respectively. At the 6-month time point,
the most common causative pathogens for proven/probable
IFIs were Aspergillus spp., i.e. in 17 ﬂuconazole and nine vo-
riconazole patients (p 0.09); Candida spp. were causative in
ﬁve patients treated with ﬂuconazole and in three patients
treated with voriconazole, zygomycetes in three ﬂuconazole
patients and one voriconazole patient, and other fungi in one
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FIG. 1. Kaplan–Meier estimates of fungal-free (proven/probable/pre-
sumptive) survival (a) and overall survival (b) up to 12 months in a
large, randomized, controlled trial comparing voriconazole and ﬂuco-
nazole for primary prophylaxis of invasive fungal infections in alloge-
neic haematopoietic stem cell transplant recipients [34]. Reproduced
with permission of the American Society of Hematology, from Win-
gard et al. [34]; permission conveyed through Copyright Clearance
Center, Inc.
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patient in each arm [34]. Based on the results of this study,
voriconazole and ﬂuconazole seem to have similar efﬁcacy
for reducing mortality in standard-risk allograft recipients
when used in the context of intensive IFI monitoring and
structured empiric antifungal therapy. Interestingly, there was
a relatively high rate of such empiric therapy for possible IFI
in both arms (voriconazole 24%, ﬂuconazole 30%, p 0.11),
which may partially account for the lack of differences
between both agents and the low overall incidence of IFI.
These results—i.e. no differences in survival rates but a
trend towards reduced frequency of IA—mirror the ﬁndings
from a clinical trial comparing posaconazole and ﬂuconazole
in the same setting. That latter trial exclusively enrolled high-
risk allogeneic HCT patients with GvHD, and although crude
mortality and total IFI rates were similar for both agents, po-
saconazole was superior in reducing IA, breakthrough IFIs
and attributable mortality [46]. Girmenia et al. [80] recently
questioned whether the patient population of the voriconaz-
ole trial was at sufﬁciently high risk of IFI when contrasted
with the posaconazole study. Of note, exploratory analyses
showed that in the higher-risk subpopulation of patients with
acute myeloid leukaemia, voriconazole may have signiﬁcantly
improved 6-month fungal-free survival (78% versus 61%,
p 0.04) and reduced incidence of IFI (9% versus 21%, p 0.04)
compared with ﬂuconazole [34,80].
Based on the outcomes from the large randomized trials
discussed so far, it seems that treatment differences between
antifungals used for prophylaxis of IFIs in allogeneic HCT
recipients are relatively difﬁcult to detect when using crude
survival or overall IFI incidence alone as the primary end-
points. This may particularly be the case when the study
design permits the use of empirical/pre-emptive therapy for
suspected IFIs, a useful approach that mimics clinical reality
and has been allowed in all major antifungal prophylaxis trials
published to date.
Composite endpoints combining outcomes—such as IFI
incidence, survival, other licensed antifungal therapy use, and
treatment tolerability—may therefore be a valuable alterna-
tive measure for detecting treatment differences in the set-
ting of antifungal prophylaxis in haematology patients. The
IMPROVIT study, a large clinical trial evaluating voriconazole
against itraconazole as primary prophylaxis in allogeneic
HCT recipients, took such an approach [32].
This study was a prospective, phase III, randomized, open-
label, multi-centre clinical trial. Eligible patients were
‡12 years of age and were to receive full-intensity or
reduced-intensity allogeneic HCT for acute leukaemia, trans-
formed chronic myeloid leukaemia, or failure of lymphoma
therapy. Patients were randomly assigned to either vorico-
nazole or itraconazole in a 1:1 ratio and were stratiﬁed by
donor source (i.e. sibling or unrelated donor) and condition-
ing regimen (i.e. full or reduced intensity).
Following intravenous loading, both voriconazole and itr-
aconazole were administered orally at 200 mg twice daily.
Prophylaxis was to be initiated on the day of stem cell infu-
sion (day 1) until day 100; antifungal prophylaxis could be
continued for a further 80 days if predeﬁned IFI risk factors
persisted. All patients were followed for £180 days. Empirical
antifungal therapy could be employed for £14 days in case of
possible IFI. The primary endpoint of the trial was success of
antifungal prophylaxis at day 180, which was deﬁned as fun-
gal-free survival to day 180 without having discontinued
study treatment for >14 days in total before day 100 [32].
The modiﬁed intent-to-treat population included a total of
224 patients in the voriconazole and 241 in the itraconazole
arm. Both treatment groups were similar in terms of baseline
characteristics (including underlying disease, conditioning reg-
imen and T-cell depletion) and speciﬁc IFI risk factors (i.e.
the incidence of overall GvHD as well as liver-speciﬁc
GvHD). Superiority of voriconazole was concluded for the
primary endpoint: success of antifungal prophylaxis at day
180 was attained by 49% of voriconazole and 33% of itraco-
nazole patients (p <0.01) and did not vary across randomiza-
tion strata. Voriconazole was also superior to itraconazole at
day 100 (Fig. 2) [32]. The superiority of voriconazole was
mostly the result of differences in the numbers of patients
who received the per-protocol duration of prophylaxis (vo-
riconazole: 54%; itraconazole: 39%; p <0.01).
The most common reasons for early treatment discontin-
uation were adverse events (23.2%) and study drug intoler-
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FIG. 2. Prophylactic success (composite endpoint combining fungal-
free survival and sufﬁcient duration of prophylaxis; adjusted for con-
ditioning regimen and donor relatedness) at day 100 and day 180 in
a large, randomized, controlled trial comparing voriconazole and itr-
aconazole for primary prophylaxis of invasive fungal infections in allo-
geneic haematopoietic stem cell transplant recipients [32].
Voriconazole was superior (p <0.01) to itraconazole at both time
points.
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ance (21.6%) in the case of itraconazole and the occurrence
of adverse events (29.9%) with voriconazole; side effects that
limited itraconazole therapy were mostly related to gastroin-
testinal intolerance. Itraconazole-treated patients had almost
30 days less of prophylaxis, with a median treatment dura-
tion of 68 days compared with 96 days with voriconazole
(p <0.01) [32]. These results suggest that voriconazole has
better long-term treatment tolerance than itraconazole. As
allogeneic HCT recipients probably require sustained dura-
tions of antifungal prophylaxis [15,32], this difference may
represent an important advantage of voriconazole over itrac-
onazole.
Both treatment groups had almost identical crude survival
rates at day 100 (92% in each group) and day 180 (82% for
voriconazole and 81% for itraconazole), with the 1-year sur-
vival rates being similar (voriconazole: 74%; itraconazole:
67%; p 0.17). There were also no statistically signiﬁcant dif-
ferences in terms of proven/probable IFIs overall, docu-
mented IA in particular, breakthrough IFIs, and treatment-
emergent IFIs, even though there was a trend in all of these
secondary endpoints that appeared to favour voriconazole. A
total of eight IFIs were recorded during the trial: one proba-
ble and two proven IFI in the voriconazole and four probable
and one proven IFI in the itraconazole arm. There were no
instances of invasive zygomycosis in either treatment group.
Of note, the use of other licensed antifungal therapies, in
particular caspofungin and liposomal amphotericin B, was sig-
niﬁcantly higher in the itraconazole arm (42% versus 30%;
p <0.01); furthermore, about 14% of patients initially ran-
domized to itraconazole were switched to voriconazole as
an ‘other licensed antifungal therapy’ at some point during
the study period [32]. This more frequent use of non-study,
mould-active systemic antifungals in itraconazole patients
may partially explain the lack of signiﬁcant differences in IFI
and survival rates between the two treatments, and further
underscores the advantage of voriconazole over itraconazole
reported in this study.
Similar outcomes were observed in patients who devel-
oped grade II to IV and/or extensive chronic GvHD during
the study (voriconazole, n = 62; itraconazole, n = 64) [81].
Baseline characteristics of patients who went on to develop
GvHD were generally similar to those of patients who did
not. Success of prophylaxis at day 180 in the subpopulation
with GvHD was also signiﬁcantly higher with voriconazole
(50% versus 30%; p 0.03). The average duration of study
prophylaxis was 107 versus 84 days (p <0.01) and the pro-
portions of patients with sufﬁcient duration of prophylaxis
were 60% versus 42% (p 0.05) for voriconazole and itraco-
nazole, respectively. Similar to the overall study population,
there were no signiﬁcant treatment differences in mortality
and IFI incidence. In the subpopulation with GvHD, adverse
events leading to discontinuation of study treatment were
signiﬁcantly more frequent with itraconazole (53% versus
34%; p <0.05), especially those of a gastrointestinal nature
(16% versus 0%; p <0.01) [81].
For the overall study population, pharmacokinetic data
were available from 52% of voriconazole and 54% of itraco-
nazole patients. Among the former, 15% had trough levels,
with a median concentration of 0.85 mg/L; trough levels were
>0.5 mg/L in 65% of these patients and >1.0 mg/L in 38%. In
itraconazole patients, 10% had trough levels with a median
concentration of 0.89 mg/L; 83% and 46% of these patients,
respectively, had trough levels >0.5 and >1.0 mg/L [32].
With regard to overall patient safety, treatment-related
gastrointestinal adverse events (nausea, vomiting and diar-
rhoea) occurred more frequently with itraconazole (p £0.01
in all cases), whereas visual side effects were only reported
in voriconazole patients (5%; p <0.01). Hepatotoxicity,
including liver function test abnormalities, was also more
common with voriconazole (13% versus 5%; p <0.01). The
average number of treatment-related adverse events per
30 days of treatment was comparable (p 0.53) between vo-
riconazole (1.7; 95% CI, 1.1–2.2) and itraconazole (2.0; 95%
CI, 1.3–2.6) [32]. Both agents therefore appear to have had
a similar frequency of adverse events overall. This assump-
tion is further supported by the results of a validated patient
satisfaction questionnaire showing that treatment side effect
scores at day 14 were similar for both agents, although the
convenience and global satisfaction scores favoured vorico-
nazole.
The authors concluded that primary prophylaxis with vo-
riconazole effectively prevents IFI following allogeneic HCT,
with acceptable safety. The superiority of voriconazole in the
primary endpoint appeared to be driven mainly by its better
long-term tolerability, which was also reﬂected in higher
patient-reported treatment satisfaction scores [32]. The abil-
ity to tolerate the chosen prophylactic agent for extended
treatment durations is an important consideration, given the
fact that IFIs (especially IA) can occur up to 6 months after
transplant [82].
A number of other recent studies further support the efﬁ-
cacy of voriconazole for the primary prevention of IFIs
(especially IA) in HCT recipients at various risks of systemic
fungal disease, as well as in patients with acute myeloid leu-
kaemia. These studies were mostly retrospective/observa-
tional [68,83–87]; a randomized, placebo-controlled trial was
stopped prematurely (as the result of availability of new data
that made further comparison with placebo unethical) [88].
Preliminary favourable outcomes observed among leukaemia
patients merit further prospective evaluation of voriconazole
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as primary antifungal prophylaxis in this setting, in particular
because voriconazole may result in less toxicity than other
broad-spectrum azoles when administered concomitantly
with chemotherapy drugs that are substrates for cytochrome
P450 isozymes [66].
Given the potential cost implications of long-term antifun-
gal prophylaxis, pharmacoeconomic data on the use of voric-
onazole in this setting would be of interest. Unfortunately,
no such data are currently available. Other extended-spec-
trum azoles were demonstrated to be cost-effective com-
pared with ﬂuconazole for primary IFI prophylaxis in HCT
recipients with GvHD and in other speciﬁc groups of neu-
tropenic haematology patients [89–92]. However, some of
these analyses have potential limitations [35], and the cost-
effectiveness of voriconazole prophylaxis remains to be eluci-
dated by relevant studies.
Secondary antifungal prophylaxis
In HCT recipients and haematological malignancy patients
who survived a previous IFI, its recurrence or the develop-
ment of a new IFI are major causes of morbidity and mortal-
ity [1,93]. The rate of IFI relapse following allogeneic HCT is
between 19 and 33% [94–96] and about 16% in patients with
acute myeloid leukaemia who undergo further myelosuppres-
sive chemotherapy [1]; reactivation rates as high as 52% have
been reported during subsequent periods of neutropenia in
adults with acute non-lymphocytic leukaemia [97]. In acute
myeloid leukaemia patients with previous pulmonary IFI who
receive additional antineoplastic chemotherapy, the relapse
risk is increased in the presence of only partial resolution of
the previous IFI, prolonged neutropenia, earlier antibiotic
therapy and high-dose cytarabine [1,98]. Fortunately, in these
patients administration of broad-spectrum antifungal agents
has shown some potential in the prevention of IFI relapse or
progression, so permitting the vital continuation of treatment
even in the presence of residual IFI [99,100]. The term ‘sec-
ondary prophylaxis’ should only be applied to trials in which
all patients have no evidence of active IFI at the time of en-
rolment; in cases where patients have continued signs and
symptoms of invasive fungal disease, this is more accurately
described as treatment of IFI in partial remission.
Until recently, only limited clinical data were available in
this setting, both for voriconazole [98,101] and for other
potential prophylactic agents [102,103]. The use of vorico-
nazole as secondary antifungal prophylaxis was originally eval-
uated in a retrospective analysis of leukaemia patients with
previous IA (n = 10) or invasive candidiasis (n = 1) [98].
Nine of these 11 patients underwent allogeneic HCT,
whereas the rest received consolidation therapy for acute
leukaemia. All were given voriconazole (400 mg daily) intra-
venously or orally for a duration of 44–245 days. Encourag-
ingly, no relapse of IFI was reported and the scheduled
treatment was delayed in only a single case. Furthermore,
with the exception of one patient who experienced visual
disturbances and another with abnormal liver function tests
secondary to hepatic GvHD, voriconazole appeared to be
well tolerated. The authors concluded that voriconazole may
be of value as secondary prophylaxis in leukaemia patients
during at-risk periods and recommended prospective trials
[98]. A comparable retrospective study of oral voriconazole
(200 mg twice daily) was later conducted in patients with a
previous diagnosis of possible (n = 20) or proven (n = 2) IFI,
who subsequently received further treatment for haemato-
logical malignancy [101]; however, it should be noted that
most patients only had partial remission of their IFI at enrol-
ment. Similarly, a small, prospective, open-label trial evaluat-
ing liposomal amphotericin B followed by oral voriconazole
for secondary prophylaxis of IA after allogeneic HCT in pae-
diatric patients also enrolled mostly patients (nine of 11)
with merely partial remission of their IFI at the time of trans-
plantation [104]. Of the eight patients who survived to day
180 after transplant, six showed complete resolution of pul-
monary inﬁltrates, one partial resolution, and one ongoing
resolution. However, because of the nature of the study
population, this trial cannot be considered a true secondary
prophylaxis study.
A much larger prospective, open-label, multicentre study
of secondary prophylaxis with voriconazole was recently
published, focusing on the prevention of recurrent IFI in
adult allogeneic HCT recipients [93]. Study participants were
required to have had a proven/probable IFI £12 months
before transplant, according to modiﬁed consensus criteria,
and could receive allogeneic HCT for any disease and with
any conditioning regimen. Patients with evidence of active
IFI, a history of zygomycosis, previous failure of voriconazole
in antifungal therapy, or signiﬁcant hepatic or renal impair-
ment were excluded. Voriconazole was initiated ‡48 h after
completion of conditioning chemotherapy and £3 days
before stem cell infusion. Antifungal prophylaxis was planned
for a minimum duration of 100 days and could be extended
by £50 days in case of neutropenia, recent administration of
immunosuppressants, or of anti-thymocyte globulin at day
100; patients could switch freely between the intravenous
and oral formulations, and were followed for at least
12 months. The primary efﬁcacy endpoint of the study was
the incidence of proven/probable IFI at 12 months [93].
Of the 45 patients enrolled, 91% had acute leukaemia as
their underlying condition. Haematological disease was in
ﬁrst complete remission in 53%. Previous IFIs were proven
IA (n = 6), probable IA (n = 25), proven invasive candidiasis
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(n = 5), other proven IFI (n = 3), or other probable IFI
(n = 3). In the remaining three patients, a previous systemic
fungal infection could not be conﬁrmed. It should be noted
that 78% of all patients had received voriconazole as treat-
ment for their previous IFI; the median time between resolu-
tion of previous IFI and the date of HCT was 59 days (range:
3–311 days). The median duration of subsequent voriconaz-
ole prophylaxis was 94 days (range: 5–180 days). Eleven
patients (24%) had died at 12 months’ follow-up, only one as
the result of an IFI. A total of three IFIs occurred after trans-
plant: two relapses (one candidaemia and one fatal scedos-
poriosis) and one new zygomycosis in a patient with
previous IA. Although 31/42 (74%) of the enrolled patients
had previous proven or probable IA, no case of IA was
observed after transplant in the entire cohort. Overall, the
1-year cumulative IFI incidence was about 7%, considerably
lower than the relapse rate reported in previous series.
Treatment-related adverse events (liver toxicity) led to the
withdrawal of two patients from the study [93].
Finally, a recent, small case series from Japan assessed vo-
riconazole as secondary prophylaxis in 15 patients with acute
leukaemia. All patients had previously been successfully trea-
ted with oral voriconazole for a primary pulmonary IFI, and
subsequently received voriconazole as secondary prophylaxis
during additional rounds of chemotherapy (35 courses in
total). In this study, 93% of patients successfully completed
their planned leukaemia therapy without signiﬁcant toxicity
or suspected IFI. The authors suggested that, based on their
results and a review of the literature, voriconazole may be a
useful option for secondary antifungal prophylaxis during my-
elosuppressive therapy [99]. Based on the body of available
data, secondary prophylaxis with voriconazole therefore
appears to be safe and effective in preventing the recurrence
of IFI following allogeneic HSCT, and possibly also in patients
with haematological malignancy undergoing cancer chemo-
therapy [93,98,99,101,104].
Guidelines on antifungal prophylaxis
Important European guidelines on antifungal prophylaxis
include those recently released by the 3rd European Confer-
ence on Infections in Leukaemia (ECIL-3) [56]. ECIL-3 uses
the original Infectious Diseases Society of America (IDSA)
grading system for quality of evidence and strength of rec-
ommendations (see Table 2A for details). These consensus
recommendations divide high-risk haematology patients into
three groups for the purpose of assigning the most appropri-
ate agent for primary antifungal prophylaxis (Fig. 3) [56].
During induction chemotherapy for acute leukaemia, for
example, the most strongly recommended agent is posaco-
nazole (AI grading of evidence), followed by aerosolized lipo-
somal amphotericin B in combination with ﬂuconazole (BI),
ﬂuconazole (CI), itraconazole (CI) and polyenes (CI). The
second patient group consists of allogeneic HCT recipients
during the neutropenic phase, for whom voriconazole (provi-
sional AI, pending the ﬁnal publication of the randomized
studies comparing voriconazole with ﬂuconazole and itraco-
nazole [32,34]) and ﬂuconazole (AI) are most strongly rec-
ommended; alternatives include itraconazole (BI), aerosolized
TABLE 2. Quality of evidence and strength of recommendations used in (A) the Infectious Diseases Society of America
(IDSA) guidelines [59,105] and in (B) the updated European Conference on Infections in Leukaemia (ECIL)-3 guidelines [56]
Quality of evidence Strength of recommendations
(A) IDSA guidelines
I: Evidence from at least one properly randomized, controlled trial A: Good evidence to support recommendation
II: Evidence from at least one well-designed clinical trial without randomization; cohort or
case–controlled analytic studies (preferably from more than one centre); multiple time-series
studies; or dramatic results from uncontrolled experiments
B: Moderate evidence to support recommendation
III: Evidence from opinions of respected authorities based on clinical experience, descriptive
studies or expert committees reports
C: Poor evidence to support recommendation
(B) ECIL-3 guidelines
I: Evidence from at least one well-executed randomized trial A: Strongly recommended—strong evidence for
efﬁcacy and substantial clinical beneﬁt
II: Evidence from at least one well-designed clinical trial without randomization; cohort or
case–controlled analytic studies (preferably from more than one centre); multiple time-series
studies; or dramatic results from uncontrolled experiments
B: Generally recommended—strong/moderate
evidence for efﬁcacy, but only limited clinical beneﬁt
III: Evidence from opinions of respected authorities based on clinical experience, descriptive
studies, or expert committees reports
C: Optional—insufﬁcient evidence for efﬁcacy;
or efﬁcacy does not outweigh possible adverse
consequences (for example, drug toxicity or interactions) or
cost of chemoprophylaxis or alternative approaches
D: Generally not recommended—moderate evidence
against efﬁcacy or for adverse outcome
E: Never recommended—strong evidence
against efﬁcacy or for adverse outcome
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liposomal amphotericin B in combination with ﬂuconazole
(BII), polyenes (CI) and micafungin (CI). Finally, for allogeneic
HCT patients with GvHD, posaconazole (AI) and voriconaz-
ole (provisional AI, pending the ﬁnal publication of the ran-
domized studies comparing voriconazole with ﬂuconazole
and itraconazole [32,34]) are suggested as the ﬁrst-line
choices for primary prophylaxis, followed by itraconazole
(BI), ﬂuconazole (CI) and polyenes (CI). The guidelines sug-
gest that serum drug concentrations of posaconazole and itr-
aconazole be monitored irrespective of group, to ensure
therapeutic levels of these agents. The ECIL-3 recommenda-
tions suggest the use of secondary antifungal prophylaxis dur-
ing an episode of prolonged neutropenia or severe
immunosuppression following a previous documented IFI (AII
grading). No particular antifungal is suggested as ﬁrst choice
in this setting; rather, selection of an appropriate prophylac-
tic drug should be based on the speciﬁc pathogen causative
of the previous IFI and the response to antifungal therapy
during that episode [56].
Guidelines on antifungal prophylaxis in haematology
patients have also been jointly released by the Center for
International Blood and Marrow Transplant Research, the
European Blood and Marrow Transplant Group, the Ameri-
can Society of Blood and Marrow Transplantation, the Cana-
dian Blood and Marrow Transplant Group, the IDSA, the
Centers for Disease Control and Prevention, and a number
of other societies [106,107]; these guidelines also use the
original IDSA evidence grading system (Table 2A). These
guidelines recommend ﬂuconazole (at doses ‡200 mg/day) as
the drug of choice for preventing invasive candidiasis, other
than that caused by Candida krusei or Candida glabrata, in
allogeneic HCT recipients in the period before engraftment
(AI grading); micafungin can be used as an alternative in this
setting (BI). For the prevention of invasive candidiasis during
the post-engraftment period, both voriconazole (BI) and po-
saconazole (BI) are recommended as suitable options. The
guidelines also recommend the chemoprophylaxis of mould
infections in patients at higher risk of such IFIs (BI), either
with itraconazole (BI), posaconazole (in patients with GvHD;
BI), or aerosolized liposomal amphotericin B (BII). The group
did not comment on voriconazole as primary antifungal pro-
phylaxis in HCT patients, because the results of the clinical
trials comparing voriconazole with ﬂuconazole [34] and itrac-
onazole [32] were not available at the time. Finally, second-
ary prophylaxis with a mould-active agent is recommended
in HCT recipients with previous IA (AII), and voriconazole is
listed as a speciﬁc option in this setting (AII) [106,107].
Other key international guidelines include those developed
by the IDSA on the management of IA, which are based on
the revised IDSA evidence grading system (see Table 2B for
details); these guidelines give an AI grading to posaconazole
for primary prophylaxis in HCT recipients with GvHD and
neutropenic patients with acute myeloid leukaemia or myelo-
dysplastic syndrome, who are at high risk for IA [59].
Most current clinical guidelines recommend posaconazole
as the main choice for primary antifungal prophylaxis in key
high-risk populations, i.e. during induction chemotherapy for
leukaemia and in allogeneic HCT recipients during the GvHD
phase [56,107,108]. However, although posaconazole pro-
phylaxis yielded clear beneﬁts over ﬂuconazole in some pop-
ulations, it is not apparent whether any single mould-active
agent is superior for the prevention of IFIs [35]. Other
mould-active antifungals, such as voriconazole, may therefore
also be valuable options in these settings.
Type of patient?
• AI: posaconazole
• BI: aerosolized liposomal 
 AmB + oral fluconazole
• CI: IV/oral fluconazole; 
 oral itraconazole solution; 
 IV polyenes 
• Insufficient data:
 IV echinocandins
• AI: IV/oral fluconazole
• AI (provisional): oral 
 voriconazole
• BI: itraconazole (IV then oral 
 solution)
• BII: aerosolized liposomal 
 AmB + oral fluconazole
• CI: IV micafungin; IV polyenes
• No data: posaconazole
• AI: oral posaconazole
• AI (provisional): oral 
 voriconazole
• BI: itraconazole (IV then oral 
 solution)
• CI: oral/IV fluconazole; 
 IV polyenes
• Insufficient data:
 IV echinocandins; aerosolized 
 liposomal AmB + oral 
 fluconazole
Leukaemia patients,
induction chemotherapy
Allo-HCT recipients,
initial neutropenic phase
Allo-HCT recipients,
GvHD phase
Treatment options?
FIG. 3. Patient risk stratiﬁcation and treatment recommendations for primary antifungal prophylaxis in haematology patients as per the ECIL-3
guidelines [56]. AmB, amphotericin B; GvHD, graft-versus-host disease; HCT, haematopoietic stem cell transplant; IV, intravenous.
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Used as primary antifungal prophylaxis in allogeneic
HCT recipients, voriconazole and posaconazole share a
number of similarities: both are effective in patients with
post-transplant GvHD, may require therapeutic drug moni-
toring to ensure efﬁcacy of antifungal prophylaxis, are avail-
able as oral formulations, and are clinically active against
moulds as well as yeasts. Furthermore, both voriconazole
and posaconazole share gastrointestinal and hepatic side
effects as some of their key treatment-related adverse
events [49,50]. Similar to the known safety proﬁle of vo-
riconazole [32], posaconazole has been associated with
prophylaxis-related hepatotoxicity [46]. However, there are
also a number of differences between the two agents.
Unlike voriconazole, posaconazole could prevent invasive
zygomycosis, even though this protection is not absolute
[109]. On the other hand, voriconazole is available as an
intravenous formulation to allow continued treatment in
case of issues with oral absorption (an intravenous formu-
lation of posaconazole is currently in development), has
been successfully evaluated against another mould-active
agent in allogeneic HCT recipients, is widely regarded as
the reference standard for treating IA (the most prevalent
IFI in this setting), and has also been shown to be effective
in HCT patients without GvHD. Furthermore, although
data exist on the efﬁcacy and safety of prophylactic vorico-
nazole in young children [34], there are currently no pro-
spective trial data for posaconazole in patients younger
than 13 years old. Future recommendations on antifungal
prophylaxis in haematology patients can therefore be
expected to take into account the results of recent studies
with voriconazole.
Conclusion
Based on a growing body of data, voriconazole appears to
be effective for the primary and secondary prevention of IFIs
in haematology patients, in particular HCT recipients. Voric-
onazole is generally safe and well tolerated in these popula-
tions, in accordance with its known overall safety proﬁle.
Randomized controlled trials evaluating voriconazole as pri-
mary antifungal prophylaxis in neutropenic patients treated
for haematological malignancies merit implementation. Fur-
thermore, prospective epidemiological studies assessing the
possible impact of voriconazole prophylaxis on the incidence
of zygomycosis may also be of value, as would be investiga-
tions to establish a potential therapeutic range of voriconaz-
ole plasma concentrations and possible dose adjustments
during concomitant treatment with hepatically metabolized
chemotherapy.
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